Equine Encephalitis - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 51
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EBB3B074B63EN
Leaflet:

Download PDF Leaflet

Equine Encephalitis - Pipeline Review, H2 2016
Equine Encephalitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Equine Encephalitis Overview
Therapeutics Development
Pipeline Products for Equine Encephalitis - Overview
Pipeline Products for Equine Encephalitis - Comparative Analysis
Equine Encephalitis - Therapeutics under Development by Companies
Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
Equine Encephalitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Equine Encephalitis - Products under Development by Companies
Equine Encephalitis - Products under Investigation by Universities/Institutes
Equine Encephalitis - Companies Involved in Therapeutics Development
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Equine Encephalitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DEF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSI-GSD-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Western Equine Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Westrern Equine Encephalitis Virus Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Equine Encephalitis - Dormant Projects
Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 51

LIST OF TABLES

Number of Products under Development for Equine Encephalitis, H2 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016
Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016
Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016
Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Equine Encephalitis - Dormant Projects, H2 2016 47

LIST OF FIGURES

Number of Products under Development for Equine Encephalitis, H2 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Eastern Equine Encephalitis - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 31 pages
Western Equine Encephalitis - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 37 pages
Eastern Equine Encephalitis - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 30 pages
Western Equine Encephalitis - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 27 pages
Japanese Encephalitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 43 pages

Ask Your Question

Equine Encephalitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: